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Background. Global surveillance for vaccine preventable invasive bacterial diseases has been set up by the World Health 
Organization to provide disease burden data to support decisions on introducing pneumococcal conjugate vaccine (PCV). We pre-
sent data from 2010 to 2016 collected at the 2 sentinel sites in Ghana.
Methods. Data were collected from children <5 years of age presenting at the 2 major teaching hospitals with clinical signs of 
meningitis. Cerebrospinal fluid specimens were collected and tested first at the sentinel site laboratory with conventional microbi-
ology methods and subsequently with molecular analysis, at the World Health Organization Regional Reference Laboratory housed 
at the Medical Research Council Unit The Gambia, for identification of Streptococcus pneumoniae, Haemophilus influenzae, and 
Neisseria meningitidis, the 3 most common bacteria causing meningitis.
Results. There were 4008 suspected cases of meningitis during the surveillance period, of which 31 (0.8%) were laboratory 
confirmed. Suspected meningitis cases decreased from 923 in 2010 to 219 in 2016. Of 3817 patients with available outcome data, 
226 (5.9%) died. S. pneumoniae was the most common bacterial pathogen, accounting for 68.5% of confirmed cases (50 of 73). 
H. influenzae and N. meningitidis accounted for 6.8% (5 of 73) and 21.9% (16 of 73), respectively. The proportion of pneumococcal 
vaccine serotypes causing meningitis decreased from 81.3% (13 of 16) before the introduction of 13-valent PCV (2010–2012) to 
40.0% (8 of 20) after its introduction (2013–2016).
Conclusions. Cases of suspected meningitis decreased among children <5 years of age between 2010 and 2016, with declines in 
the proportion of vaccine-type pneumococcal meningitis after the introduction of 13-valent PCV in Ghana.
Keywords. bacterial meningitis; pneumococcal conjugate vaccine.
The highest burden of bacterial meningitis are in sub-Saharan 
Africa [1–4]. The predominant causative pathogens beyond the 
neonatal period are Streptococcus pneumoniae, Haemophilus 
influenzae, and Neisseria meningitidis. Besides endemic cases, 
seasonal epidemics occur during the dry hot season within 
the meningitis belt in sub-Saharan Africa, caused mainly by 
N.  meningitidis, although pneumococcal outbreaks have also 
been reported [5–8].
Reported case fatality rates (CFRs) for meningitis are high. 
Global burden estimates for the Africa in 2015 were 15% (un-
certainty ranges, 10%–15%) and 28% (uncertainty ranges, 
20%–37%) for pneumococcal and H.  influenzae type b (Hib) 
CFRs [4], respectively. The highest recorded CFRs were in the 
African continent [4]. The CFRs for meningococcal meningitis 
were lower in developing countries, at about 10%–15% [9, 10]. 
One in 5 meningitis survivors in Africa develop neurological 
sequelae while in the hospital [11]. Sequelae after discharge 
from hospital have also been reported [12, 13]. S. pneumoniae 
causes more sequelae than the other 2 bacteria. Globally, the 
median risk of at least 1 major sequela was estimated at 25%, 
10%, and 7% for pneumococcal, Hib, and meningococcal men-
ingitis, respectively [14]. Hearing loss was the most common 
major sequela, and others include seizures and mental retarda-
tion, all of which may be temporary or may result in long-term 
disability. Bacterial meningitis has huge economic implications 
for healthcare providers and families [15, 16].
S90 • cid 2019:69 (Suppl 2) • Renner et al
Inappropriate use of antibiotics coupled with antimicrobial 
resistance make diagnosis and treatment of bacterial infections 
challenging in developing countries. The World Health 
Organization (WHO) recommends the inclusion of conjugate 
Hib vaccines in all infant immunization programs, pneumo-
coccal conjugate vaccines (PCVs), particularly in countries with 
high childhood mortality rates (ie, >50 deaths per 1000 births in 
children <5 years old), and large-scale meningococcal vaccina-
tion programs in countries with high or intermediate endemic 
rates of invasive meningococcal disease (>10 or 2–10 cases per 
100 000 population per year, respectively) and those with fre-
quent epidemics [17–19]. With support from Gavi, the Vaccine 
Alliance, these vaccines are now available in many African 
countries [20].
Ghana introduced Hib-containing (pentavalent) vac-
cine in 2002 and a 13-valent PCV (PCV13) in May 2012. 
A  MenAfriVac mass vaccination campaign was carried out 
in 2012 in the 3 northern regions within the meningitis belt. 
Coverage for 3 doses of Hib has been >80% since introduc-
tion of that vaccine and coverage for 3 doses of PCV increased 
from about 40% in 2012 to >90% in 2016. The national prev-
alence of human immunodeficiency virus was 2.4% in 2016 
[21], The country has a tropical climate with 2 seasons, a wet 
season from March/April to November and a dry season the 
rest of the year, with some differences between the northern 
and southern regions. Malaria is endemic and peaks just after 
the rainy season. The gross national income per capita for 
2016 was $1308 [22].
In 2008, WHO set up the Global Invasive Bacterial Vaccine-
preventable Diseases surveillance network to better describe 
disease epidemiology, measure vaccine impact, and charac-
terize circulating bacterial strains [23]. In Ghana, the surveil-
lance focuses on meningitis at 2 sentinel sites. Here we present 
2010–2016 surveillance data from these 2 sites.
METHODS
Study Setting
Ghana is located on the west coast of Africa with an estimated 
population of about 28 million in 2016 [22]. Children <5 years of 
age represent 20% of the population. The 2 sentinel sites within 
the Global Invasive Bacterial Vaccine-preventable Diseases net-
work are located at the Korle-Bu and Komfo Anokye teaching 
hospitals, in the greater Accra region and the Ashanti region, 
respectively, both outside the meningitis belt. Korle-Bu is the 
main national referral center and the only public tertiary hos-
pital in Southern Ghana, and Komfo Anokye is the second 
largest hospital in the country and the only tertiary hospital 
in the Ashanti region. The former is in the central inland area 
and the latter on the coast. Both sites are served by the WHO 
Regional Reference Laboratory (RRL) housed at the Medical 
Research Council unit The Gambia (MRCG).
Patients
Data were collected for children <5 years of age presenting at 
either of the 2 sentinel hospitals with suspected meningitis. 
Information on demographics, vaccination history (recorded 
date of vaccine dose), clinical symptoms, antibiotics use be-
fore admission, final diagnosis, and outcome at discharge were 
recorded on a case report form. Cerebrospinal fluid (CSF) 
specimens were obtained from the children unless clinically 
contraindicated.
Laboratory Methods
All CSF specimens were cultured at the sentinel sites for isola-
tion of S. pneumoniae, H. influenzae, and N. meningitidis, using 
appropriate selective media and following standard methods 
[24]. Appearance and results of microscopy, gram stain, se-
rology, and culture, when available, were recorded. Isolates from 
positive samples were sent to the RRL. In addition, aliquots of 
all negative CSF specimens (ie, CSF with no growth on culture) 
were also sent to the RRL from 2010 to 2013; from 2014, all CSF 
specimens were shipped to the RRL, irrespective of the culture 
result. At the RRL, molecular analysis with quantitative poly-
merase chain reaction (PCR) was conducted to confirm spe-
cific causative pathogen and to serogroup/serotype the species 
detected [24]. If a bacterial isolate was available, serotyping 
was conducted using latex agglutination. Whole-genome 
sequencing was performed on available purified pneumococcal 
isolates extracted from fresh overnight culture. using methods 
described elsewhere [25] and displaying the results on a phylo-
genetic tree with the Web-based Interactive tree of life (iTOL) 
tool (version 3) [26].
Case Definitions
A case of suspected meningitis was defined as any child aged 
0–59  months admitted with sudden onset of fever (>38.5°C 
rectal or >38.0°C axillary) and 1 of the following signs: neck 
stiffness, altered consciousness with no other alternative diag-
nosis, or other meningeal sign.
Based on laboratory findings, suspected cases were 
categorized as probable or confirmed. A probable case was one 
with turbid or cloudy CSF appearance or microscopy and /bio-
chemistry showing a white blood cell count >100/μL or a white 
blood cell count 10–100/μL and either CSF protein >100 mg/
dL or CSF glucose <40 mg/dL. A confirmed case was one with 
S. pneumoniae, H.  influenzae or N. meningitidis isolated from 
the CSF culture or positive results of serology and/or PCR.
Statistical Analysis
All data were entered in an Epi Info database tool at the site 
and forwarded to the RRL, where additional laboratory data 
were entered. The children’s demographic characteristics and 
clinical outcomes and the distribution of cases over time were 
described. Proportions were based on the number of cases with 
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available data for each variable. The variables of age, final diag-
nosis, and antibiotic use before hospitalization were compared 
between children who died and those that survived, using χ 2 or 
Fisher exact tests as appropriate. The number of vaccine dose 
was derived from the number of vaccination dates recorded—1, 
2, or 3. The proportions of pathogens causing meningitis were 
also calculated, and a Poisson regression model was used to as-
sess the effects of the pre-PCV13 (2010–2012) and post-PCV13 
(2013–2016) periods on the proportion of PCV13 vaccine-type 
(VT) isolates.
After CSF processing at the RRL, some results could not be 
linked to the metadata from the site. In a separate analysis, we 
included all confirmed pathogens irrespective of the labora-
tory and demographic data linkage. Statistical analyses were 
performed using Stata 14 software [27].
Ethical Review and Approval
Ethical approval was not a requirement in Ghana for routine 
meningitis surveillance, including drug susceptibility testing 
of collected isolates as this approved within the routine diag-
nostic algorithm at the Ministry of Health. However, the sur-
veillance received overarching ethical approval (SCC1188) by 
the joint MRCG Gambia Government ethics board that allowed 
the analysis of collected West African isolates at MRCG at the 
London School of Hygiene and Tropical Diseases.
RESULTS
Of the 4008 suspected meningitis cases identified from 2010 
to 2016 at the 2 sentinel sites, 2561 (63.9%) occurred in chil-
dren from the Ashanti region, 1160 (28.9%) in children from 
greater Accra, and 287 (7.2%) in children from other regions. 
(Table 1). The median (IQR) age of case patients was 12 (2–25) 
months, and 2154 (53.7%) were male. Among children with 
available data, 60.4% (915 of 1515) had received antibiotics be-
fore admission.
Ninety-one percent of the children did not have any vaccina-
tion date recorded for PCV13, and 60% did not have Hib vacci-
nation date recorded. Among those with records, 8.9% (303 or 
3408) and 47.9% (1510 of 3150) received 2 or 3 doses of PCV13 
and Hib vaccine, respectively (Table 1). There was no record of 
MenAfriVac vaccination.
The number of suspected cases decreased from 923 in 2010 
to 219 in 2016. Monthly trends were observed, with peaks of 
suspected cases in the first 2 quarters of each year, except for 
2010 when the peak was in the third quarter (Figure 1).
Of 3817 children with available outcome data, 226 (5.9%) 
died (Table 1). The percentage that died did not differ between 
the pre-PCV13 and post-PCV13 periods (Table 2). The CFR 
was 4.7% in 2010 and 5.5% in 2016, with the highest number 
of deaths recorded in 2013 (53 of 226). Among those with a 
reported final diagnosis from a clinician, septicemia was the 
most common diagnosis (547 of 1353 [40.4%]), followed by 
meningitis (211 of 1353 [15.6%]).
Only 31 cases (0.8%) were confirmed meningitis and 387 
(9.7%) were probable meningitis. Twenty-seven bacterial isolates 
Table 1.   Characteristics of Children With Suspected Meningitis 
(N = 4008)
Characteristic Children, No. (%)
Age, mo  
 0–11 1853 (46.2)
 12–23 729 (18.2)
 24–59 1419 (35.4)
 Unknown 7 (0.2)
Sex  
 Male 2155 (53.8)
 Female 1853 (46.2)
Region  
 Ashanti 2561 (63.9)
 Greater Accra 1160 (28.9)
 Other 287 (7.2)
Case type  
 Confirmed 31 (0.8)
 Probable 387 (9.7)
 Suspected 3590 (89.5)
Final diagnosisa  
 Pneumonia 83 (2.1)
 Meningitis 211 (5.3)
 Septicemia 547 (13.6)
 Other 512 (12.8)
 Unknown 2655 (66.2)
Comorbidity  
 No 1138 (28.4)
 Yes 157 (3.9)
 Unknown 2713 (67.7)
Antibiotics before admission  
 No 600 (15.0)
 Yes 915 (22.8)
 Unknown 2493 (62.2)
Outcome  
 Discharged alive 3591 (89.6)
 Died 226 (5.6)
 Unknown 191 (4.8)
No. of vaccine doses  
 PCV13b  
  1 33 (0.8)
  2 49 (1.2)
  3 254 (6.3)
  Not recordedc 3672 (91.6)
 Hib vaccineb  
  1 78 (1.9)
  2 141 (3.5)
  3 1369 (34.2)
  Not recordedc 2420 (60.4)
Abbreviations: Hib, Haemophilus influenzae type b; PCV13, 13-valent pneumococcal con-
jugate vaccine. 
aFinal diagnosis according to the clinician.
bDoses derived from the actual number of dates recorded for 1, 2, or 3 doses.
cNo record of vaccination date for all 3 doses.
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and 887 CSF samples were sent to the RRL (Figure 2). The total 
number of confirmed cases from the laboratory data was 73, but 
42 confirmed cases were not linked to the demographic data. 
Of the 73 confirmed cases, 50 (68.5%) were S.  pneumoniae, 5 
(6.8%) were H. influenzae, 16 (21.9%) were N. meningitidis, and 
2 were mixed pathogens (1 H. influenzae and S. pneumoniae and 
1 H. influenzae and N. meningitidis. The annual distributions of 
confirmed isolates for the 3 bacteria are shown in Figure 3.
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Figure 1. Quarterly distribution of suspected cases and deaths from 2010 through 2016.
Table 2.  Factors Associated With Death Among Children With Suspected Meningitis
Factor 
Suspected Cases
P Value Patient Survived, No. (%) Patient Died, No. (%) Total, No.
Case type     
 Confirmed 25 (86.2) 4 (13.8) 29 .01
 Probable 338 (91.4) 32 (8.6) 370 
 Suspected 3228 (94.4) 190 (5.6) 3418
 Total 3591 (94.1) 226 (5.9) 3817
Patient age, mo     
 0–11 1653 (93.1) 123 (6.9) 1776 .02
 12–23 648 (93.8) 43 (6.2) 691 
 24–59 1283 (95.5) 60 (4.5) 1343 
 Total 3584 (94.1) 226 (5.9) 3810 
Final diagnosisa     
 Meningitis 201 (95.3) 10 (4.7) 211 .02
 Pneumonia 75 (90.4) 8 (9.6) 83 
 Septicemia 529 (96.7) 18 (3.3) 547 
 Other 498 (97.3) 14 (2.7) 512 
 Total 1303 (96.3) 50 (3.7) 1353
PCV era     
 Pre-PCV era 2045 (94.3) 123 (5.7) 2168 .46
 Post-PCV era 1546 (93.7) 103 (6.3) 1649 
 Total 3591 (94.1) 226 (5.9) 3817  
Antibiotics before admission     
 No 559 (95.6) 26 (4.4) 585 .14
 Yes 877 (97.0) 27 (3.0) 904
 Total 1436 (96.4) 53 (3.6) 1489 
Abbreviation: PCV, pneumococcal conjugate vaccine. 
aFinal diagnosis according to the clinician.
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Forty-nine confirmed cases were serotyped or serogrouped 
(Figure 2). Of 5 H. influenzae cases typed, 1 was Hib, 1 type c, 2 
type e and 1 nontypable. Similarly, of the 8 N. meningitidis cases 
typed, 1 was serogroup W, 4 serogroup B, 1 serogroup X, and 1 
serogroup Y; 1 isolate was not grouped. Among the 36 pneumo-
coccal meningitis cases, 21 (58.3%) were VT disease. The pro-
portion of VT pneumococcal meningitis cases declined from 
81.3% (13 of 16) to 40.0% (8 of 20), with a prevalence ratio of 
0.49 (0.20–1.19) (P = .12).
Whole-genome sequencing of the 26 S. pneumoniae isolates 
that were confirmed at the RRL showed that the predominant 
lineage was ST 63 (n = 4), from serotype 14 isolates, 2 in the pre-
PCV and 2 in the post-PCV era. There was more diversity in 
the post-PCV era, with 2 ST 9929 from serotype 12F, 2 ST 2208 
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Figure 2. Flow chart of CSF sample processing. One isolate (Streptococcus pneumoniae) was not viable at the RRL. Of the CSF samples, 172 could not be linked to metadata 
from site. CSF cultures were done in 1611 cases, not done in 6, and the status was unknown in 2841. Between 2010 and 2013, culture-positive isolates and culture-negative 
CSF samples were sent to the RRL, and between 2014 and 2016, all CSF samples were sent to the RRL. Specimens were considered inconclusive if neither a pathogen nor 
the RNAse P gene was detected. Numbers of confirmed cases are displayed in red. Abbreviations: CSF, cerebrospinal fluid; PCR, polymerase chain reaction; RRL, Regional 
Reference Laboratory; WGS, whole-genome sequencing.
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serotype 24, 2 ST 4103, and 1 belonging to serogroup 9 (Figure 
4). An antibiogram showed a cluster of serotype 12F resistant 
strains (Figure 4).
DISCUSSION
We report data from hospital-based surveillance in Ghana 
within the context of conjugate vaccine use for the 3 most 
common bacteria causing meningitis in sub-Saharan Africa. 
Between 2010 and 2016, the number of suspected meningitis 
cases decreased by >70%, whereas the difference in the CFRs 
was about 1%. S.  pneumoniae was the leading etiologic path-
ogen. The proportion of PCV13-type pneumococcal meningitis 
decreased in the post-PCV era.
Our finding of seasonality of suspected cases of menin-
gitis is consistent with the pattern seen in the meningitis belt 
with peaks in the first 5 months of the year [5]. From a pooled 
analysis using country-level data before and after conjugate 
vaccines, the seasonal timing of bacterial meningitis was be-
tween February and March, during the dry season for 19 coun-
tries in the African meningitis belt. The study further suggested 
that the pattern has not changed in the postvaccination era [28].
PCVs have been shown to decrease VT pneumococcal disease 
in population-based studies from the Gambia, Mozambique 
and South Africa [29–31]. We observed that the proportion of 
PCV13-type pneumococcal meningitis decreased by 51% from 
the pre-PCV (2010–2012) to the post-PCV (2013 and 2016) era. 
Recently, concerns have been raised regarding the persistence 
of VT and emergence of non-VT in disease and carriage after 
5 years of PCV13 in the United Kingdom [32]. Carriage data in 
1 study in the subregion, 5 years after PCV13 has also shown 
persistence of VT and emergence of non-VT [33]. Because 
carriage is a precursor for disease, there is a need to continue 
monitoring, particularly in Africa where the disease burden was 
very high before vaccine introduction.
After the introduction of the Hib vaccine, Hib disease 
has diminished immensely [34–36]. Continued surveillance 
will help determine whether there are selected populations 
harboring Hib [37]. Regarding nontypable H.  influenzae, a 
review in the Hib era reported that there was no convincing 
evidence of a substantial or sustained increase after vaccina-
tion [38].
Although vaccination data were incomplete for many chil-
dren, it was not surprising that we did not observe any record 
of MenAfriVac receipt, given that mass vaccination campaigns 
were conducted in Northern Ghana in 2012 and the national 
rollout of MenAfriVac started only in 2016. We found 1 case of 
N. meningitidis serogroup W and no N. meningitidis serogroup 
Figure 4. Phylogenetic tree of pneumococcal isolates showing PCV era and antibiogram. Dashed blue line represents the reference genome. Six isolates from blood 
samples from Ghana included in the tree. Abbreviations: CHL, chloramphenicol; CTX, cotrimoxazole, ERY, erythromycin; OX, oxacillin; PCV, pneumococcal conjugate vaccine; 
TET, tetracycline. 
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A. The latter has decreased remarkably after the campaigns that 
started in 2010 in sub-Saharan Africa [5]. In a recent outbreak 
in Ghana, the main serogroup was W [8].
We have shown here that continued surveillance is useful 
to understand the epidemiology of bacterial meningitis and 
to describe changes in the etiologic pathogen as countries 
introduce new conjugate vaccines. This analysis has some 
noteworthy limitations. For some variables, the data were in-
complete, but the quality of data collection is assured because 
the surveillance system has been monitored by WHO, with 
improvements to data management that include training and 
an external quality assessment program for all laboratories, 
including the RRL [39, 40]. Although CSF specimens were 
collected from most children with suspected meningitis, de-
finitive diagnoses were lacking because an etiologic pathogen 
was rarely isolated. 
Use of antibiotics before hospitalization was common and 
may have contributed to the low yield of bacterial isolation 
from CSF specimens. Although one-third of patients had no 
reported prior antibiotic use, this does not exclude antibiotic 
consumption. One study in the Gambia showed high urine 
antibiotic activity among patients who reported no antibiotic 
use before presentation to the hospital [41]. Moreover, in more 
than half of the cases (62.5%) it was not known whether the 
child had received an antibiotic before admission. Not all the 
CSF specimens were tested with PCR, and limited bacteriolog-
ical facilities at the hospital laboratories may be a contributing 
factor for the low CSF yield.
We compared VT disease in 2 periods, before and after vac-
cine introduction, without a translation phase to account for 
vaccine uptake. The vaccine was introduced in 2012 without 
a catch-up campaign, and coverage was about 40% [42]. By 
including the year of introduction in the prevaccine period, 
we have diluted the effect of the impact. The numbers were 
small, and our prevalence ratio was not statistically signifi-
cant. Our estimates of total vaccination doses irrespective of 
age are likely to be underestimates, because many children did 
not have recorded vaccination history data. National coverage 
for 3 doses of Hib and PCV13 were both reported to be >90% 
in 2016 [42].
In conclusion, suspected and consequently confirmed cases of 
meningitis decreased from 2010 to 2016. The number of deaths 
has also decreased by about 70% over the surveillance period. 
After the introduction of PCV13 in 2012, we showed a decrease 
by 50.8% in PCV13-type pneumococcal meningitis, suggesting 
potential vaccine impact. Only 1 case of Hib meningitis and no 
N. meningitidis serogroup A was observed during the surveil-
lance period, a finding likely to be related to the introduction 
of Hib in 2002 and the location of the sentinel sites outside 
the African meningitis belt regions. Continued surveillance is 
essential to evaluate long-term vaccine impact and to monitor 
changes in the circulating bacterial strains causing disease.
Notes
Invasive Bacterial Disease (IBD) writing group. The writing group 
includes B. K. A., M. S., E. U., A. W., Uzochukwu Egere, Akram Zaman, 
Catherine Okoi, Florian Gehre, Leopold Tientcheu, N.  I. M., Felix Dube, 
P. S. N., J. M. M., Sambou Suso, Sheikh Jarju, Dam Khan, Chinelo Ebruke, 
Rowan Bancroft, and M. Antonio.
Author contributions. M. Antonio and J.  M. M.  established the 
World Health Organization (WHO) Regional Office for Africa–supported 
Paediatric Bacterial Meningitis Surveillance Network in West Africa. 
M. A. supervised the overall network, including setting up the sentinel sur-
veillance system. L. A. R., D. A., T. D., S. K. O., M. Awunyo, and B. A. clin-
ically investigated and recruited the patients at the sentinel sites, collected 
demographic data and performed microbiological testing at sentinel sites, 
and shipped cerebrospinal fluid and bacterial isolates to WHO collaborating 
center (WHOCC) at the Medical Research Council unit The Gambia 
(MRCG) for confirmatory testing and molecular analysis, supervised by 
B. K. A. and M. Antonio. Along with the IBD writing group, E. U., B. K. A., 
and M. Antonio developed the analysis plan and helped analyze and inter-
pret data. L. A. R., E. U., B. K. A. and M. Antonio drafted the manuscript. 
N. I. M. provided statistical advice. All authors helped interpret the findings 
and write the final manuscript.
Acknowledgments. The authors thank the WHO Country Office of 
Ghana and WHO Inter-country Support Team for coordination, advice, 
and support throughout the surveillance period. They also thank the sur-
veillance participants and their families in Ghana and the staff members 
and students at the WHOCC MRCG, as well as the IBD writing group for 
their advice and input. 
Disclaimer. The opinions expressed by authors contributing to 
this journal do not necessarily reflect the opinions the World Health 
Organization, the Medical Research Council Unit The Gambia at the 
London School of Hygiene and Tropical Medicine or the authors’ affiliated 
institutions.
Financial support. Financial support for sentinel site surveillance was 
provided by the Ghana Ministry of Health, Gavi - the Vaccine Alliance, 
through a grant to the WHO for the African Paediatric Bacterial Meningitis 
Surveillance Network.
Supplement sponsorship. This supplement was supported with funds 
from Gavi, the Vaccine Alliance through The World Health Organization 
and the CDC Foundation, and The Medical Research Council Unit The 
Gambia at the London School of Hygiene and Tropical Medicine.
Potential conflicts of interest. E.  U.  reports fees related to a 
GlaxoSmithKline consultancy (2014–2017), outside the submitted work. All 
other authors report no potential conflicts. All authors have submitted the 
ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the 
editors consider relevant to the content of the manuscript have been disclosed.
References
1. O’Brien KL, Wolfson LJ, Watt JP, et al; Hib and Pneumococcal Global Burden of 
Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in 
children younger than 5 years: global estimates. Lancet 2009; 374:893–902.
2. Watt JP, Wolfson LJ, O’Brien KL, et al; Hib and Pneumococcal Global Burden of 
Disease Study Team. Burden of disease caused by Haemophilus influenzae type b 
in children younger than 5 years: global estimates. Lancet 2009; 374:903–11.
3. Jafri RZ, Ali A, Messonnier NE, et al. Global epidemiology of invasive meningo-
coccal disease. Popul Health Metr 2013; 11:17.
4. Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae 
and Haemophilus influenzae type b disease in children in the era of conjugate 
vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health 
2018; 6:e744–57.
5. Lingani C, Bergeron-Caron C, Stuart JM, et al. Meningococcal meningitis surveil-
lance in the African meningitis belt, 2004–2013. Clin Infect Dis 2015; 61(suppl 
5):S410–5.
6. Kwambana-Adams BA, Asiedu-Bekoe F, Sarkodie B, et al. An outbreak of pneu-
mococcal meningitis among older children (≥5 years) and adults after the imple-
mentation of an infant vaccination programme with the 13-valent pneumococcal 
conjugate vaccine in Ghana. BMC Infect Dis 2016; 16:575.
7. Kambiré  D, Soeters  HM, Ouédraogo-Traoré  R, et  al; MenAfriNet Consortium. 
Nationwide trends in bacterial meningitis before the introduction of 13-valent pneu-
mococcal conjugate vaccine-Burkina Faso, 2011-2013. PLoS One 2016; 11:e0166384.
S96 • cid 2019:69 (Suppl 2) • Renner et al
8. Aku FY, Lessa FC, Asiedu-Bekoe F, et al. Meningitis outbreak caused by vaccine-
preventable bacterial pathogens—Northern Ghana, 2016. MMWR Morb Mortal 
Wkly Rep 2017; 66:806–10.
9. Parent du Chatelet I, Traore Y, Gessner BD, et al. Bacterial meningitis in Burkina 
Faso: surveillance using field-based polymerase chain reaction testing. Clin Infect 
Dis 2005; 40:17–25.
10. Campagne  G, Schuchat  A, Djibo  S, Ousséini  A, Cissé  L, Chippaux  JP. 
Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96. Bull World 
Health Organ 1999; 77:499–508.
11. Ramakrishnan  M, Ulland  AJ, Steinhardt  LC, Moïsi  JC, Were  F, Levine  OS. 
Sequelae due to bacterial meningitis among African children: a systematic litera-
ture review. BMC Med 2009; 7:47.
12. Edmond  K, Dieye  Y, Griffiths  UK, et  al. Prospective cohort study of disabling 
sequelae and quality of life in children with bacterial meningitis in urban Senegal. 
Pediatr Infect Dis J 2010; 29:1023–9.
13. Goetghebuer T, West TE, Wermenbol V, et al. Outcome of meningitis caused by 
Streptococcus pneumoniae and Haemophilus influenzae type b in children in The 
Gambia. Trop Med Int Health 2000; 5:207–13.
14. Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and 
regional risk of disabling sequelae from bacterial meningitis: a systematic review 
and meta-analysis. Lancet Infect Dis 2010; 10:317–28.
15. Portnoy A, Jit M, Lauer J, et al. Estimating costs of care for meningitis infections 
in low- and middle-income countries. Vaccine 2015; 33(suppl 1):A240–7.
16. Usuf  E, Mackenzie  G, Sambou  S, Atherly  D, Suraratdecha  C. The economic 
burden of childhood pneumococcal diseases in The Gambia. Cost Eff Resour 
Alloc 2016; 14:4.
17. Publication WHO. Pneumococcal vaccines WHO position paper—2012—
recommendations. Vaccine 2012; 30:4717–8.
18. World Health Organization. Haemophilus influenzae type b (Hib) vaccination 
WHO position paper: July 2013-Recommendations. Vaccine 2013; 31:6168–9.
19. Meningococcal vaccines: WHO position paper, November 2011. Releve 
Epidemiologique Hebdomadaire 2011; 86:521–39.
20. Gavi,  the  Vaccine  Alliance. Countries approved for support 2017. Available at: 
http://www.gavi.org/results/countries-approved-for-support/. Accessed 29 July 
2017.
21. Summary of the 2016 HIV sentinel survey report. Ghana, Accra: Ghana AIDS 
Commission, 2017.
22. Hill PC, Cheung YB, Akisanya A, et al. Nasopharyngeal carriage of Streptococcus 
pneumoniae in Gambian infants: a longitudinal study. Clin Infect Dis 2008; 
46:807–14.
23. Murray J, Agócs M, Serhan F, et al; Centers for Disease Control and Prevention. 
Global invasive bacterial vaccine-preventable diseases surveillance–2008-2014. 
MMWR Morb Mortal Wkly Rep 2014; 63:1159–62.
24. World Health Organization. Laboratory methods for the diagnosis of meningitis 
caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus 
influenzae. Geneva, Switzerland: WHO manual. 2nd ed. 2011.
25. Cornick JE, Chaguza C, Harris SR, et al; PAGe Consortium. Region-specific di-
versification of the highly virulent serotype 1 Streptococcus pneumoniae. Microb 
Genom 2015; 1:e000027.
26. Letunic  I, Bork  P. Interactive tree of life (iTOL) v3: an online tool for the dis-
play and annotation of phylogenetic and other trees. Nucleic Acids Res 2016; 
44:W242–5.
27. Stata statistical software: release 14. College Station, TX: StataCorp, 2015.
28. Paireau  J, Chen  A, Broutin  H, Grenfell  B, Basta  NE. Seasonal dynamics 
of bacterial meningitis: a time-series analysis. Lancet Glob Health 2016; 
4:e370–7.
29. Mackenzie GA, Hill PC, Jeffries DJ, et al. Effect of the introduction of pneumo-
coccal conjugate vaccination on invasive pneumococcal disease in The Gambia: a 
population-based surveillance study. Lancet Infect Dis 2016; 16:703–11.
30. Nhantumbo  AA, Weldegebriel  G, Katsande  R, et  al. Surveillance of impact of 
PCV-10 vaccine on pneumococcal meningitis in Mozambique, 2013 – 2015. PLoS 
One 2017; 12:e0177746.
31. von Gottberg A, de Gouveia L, Tempia S, et al; GERMS-SA Investigators. Effects 
of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med 
2014; 371:1889–99.
32. Kandasamy  R, Voysey  M, Collins  S, et  al. Persistent circulation of vaccine 
serotypes and serotype replacement after five years of UK infant immunisation 
with PCV13. J Infect Dis 2019. doi:10.1093/infdis/jiz178.
33. Usuf  E, Bottomley  C, Bojang  E, et  al. Persistence of nasopharyngeal pneumo-
coccal vaccine serotypes and increase of nonvaccine serotypes among vaccinated 
infants and their mothers 5 years after introduction of pneumococcal conjugate 
vaccine 13 in The Gambia. Clin Infect Dis 2019; 68:1512–21.
34. Adegbola RA, Secka O, Lahai G, et al. Elimination of Haemophilus influenzae type 
b (Hib) disease from The Gambia after the introduction of routine immunisation 
with a Hib conjugate vaccine: a prospective study. Lancet 2005; 366:144–50.
35. Hammitt LL, Crane RJ, Karani A, et al. Effect of Haemophilus influenzae type b 
vaccination without a booster dose on invasive H influenzae type b disease, naso-
pharyngeal carriage, and population immunity in Kilifi, Kenya: a 15-year regional 
surveillance study. Lancet Glob Health 2016; 4:e185–94.
36. Renner LA, Newman MJ, Ahadzie L, Antwi-Agyei KO, Eshetu M. Introduction 
of Haemophilus influenzae type B conjugate vaccine into routine immunization in 
Ghana and its impact on bacterial meningitis in children younger than five years. 
Pediatr Infect Dis J 2007; 26:356–8.
37. Oh SY, Griffiths D, John T, et al. School-aged children: a reservoir for continued 
circulation of Haemophilus influenzae type b in the United Kingdom. J Infect Dis 
2008; 197:1275–81.
38. Agrawal A, Murphy TF. Haemophilus influenzae infections in the H. influenzae 
type b conjugate vaccine era. J Clin Microbiol 2011; 49:3728–32.
39. World Health Organization. Invasive bacterial vaccine preventable diseases lab-
oratory network. Available at: http://www.who.int/immunization/monitoring_ 
surveillance/burden/laboratory/IBVPD/en/. Accessed 16 August 2017.
40. Report for WHO-coordinated IBVPD surveillance network, laboratory technical 
working group meeting. Geneva, Switzerland: WHO, 2014.
41. The impact of pre-hospital antibiotics on blood culture yields in a low resource 
setting. Int J Infect Dis 2016; 45:72–3.
42. World Health Organization. WHO vaccine-preventable diseases: monitoring 
system. 2017 global summary; WHO UNICEF estimates time series for Ghana 
(GHA). Geneva, Switzerland: WHO, 2017.
